New growth hormone pen under safety watch in korean kids
NCT ID NCT05509894
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tracks the safety and effectiveness of Ngenla, a growth hormone injection, in over 500 children aged 3 and older with growth hormone deficiency in Korea. Researchers will monitor side effects and growth changes over 6 years during routine medical care. The treatment helps manage the condition but does not cure it, as children need ongoing hormone therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEDIATRIC GROWTH HORMONE DEFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.